BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mohan T, Kim J, Berman Z, Wang S, Compans RW, Wang BZ. Co-delivery of GPI-anchored CCL28 and influenza HA in chimeric virus-like particles induces cross-protective immunity against H3N2 viruses. J Control Release 2016;233:208-19. [PMID: 27178810 DOI: 10.1016/j.jconrel.2016.05.021] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Mohan T, Berman Z, Kang SM, Wang BZ. Sequential immunizations with a panel of HIV-1 Env virus-like particles coach immune system to make broadly neutralizing antibodies. Sci Rep 2018;8:7807. [PMID: 29773829 DOI: 10.1038/s41598-018-25960-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
2 Zhu W, Dong C, Wei L, Wang BZ. Promising Adjuvants and Platforms for Influenza Vaccine Development. Pharmaceutics 2021;13:68. [PMID: 33430259 DOI: 10.3390/pharmaceutics13010068] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Dong C, Wang B. Engineered Nanoparticulate Vaccines to Combat Recurring and Pandemic Influenza Threats. Advanced NanoBiomed Research 2022;2:2100122. [DOI: 10.1002/anbr.202100122] [Reference Citation Analysis]
4 Liu J, Ren Z, Wang H, Zhao Y, Wilker PR, Yu Z, Sun W, Wang T, Feng N, Li Y, Wang H, Ji X, Li N, Yang S, He H, Qin C, Gao Y, Xia X. Influenza virus-like particles composed of conserved influenza proteins and GPI-anchored CCL28/GM-CSF fusion proteins enhance protective immunity against homologous and heterologous viruses. Int Immunopharmacol 2018;63:119-28. [PMID: 30081250 DOI: 10.1016/j.intimp.2018.07.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
5 Yan Yan, Jiang X, Wang X, Liu B, Ding H, Jiang M, Yang Z, Dai Y, Ding D, Yu H, Zhang S, Liu J, Sha M, Lui C, Qiu Y, Lu H, Hu Q. CCL28 mucosal expression in SARS-CoV-2-infected patients with diarrhea in relation to disease severity. J Infect 2021;82:e19-21. [PMID: 32871180 DOI: 10.1016/j.jinf.2020.08.042] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Luo Y, Mohan T, Zhu W, Wang C, Deng L, Wang BZ. Sequential Immunizations with heterosubtypic virus-like particles elicit cross protection against divergent influenza A viruses in mice. Sci Rep 2018;8:4577. [PMID: 29545521 DOI: 10.1038/s41598-018-22874-w] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
7 Mohan T, Zhu W, Wang Y, Wang BZ. Applications of chemokines as adjuvants for vaccine immunotherapy. Immunobiology 2018;223:477-85. [PMID: 29246401 DOI: 10.1016/j.imbio.2017.12.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
8 Mohan T, Deng L, Wang BZ. CCL28 chemokine: An anchoring point bridging innate and adaptive immunity. Int Immunopharmacol 2017;51:165-70. [PMID: 28843907 DOI: 10.1016/j.intimp.2017.08.012] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
9 McCraw DM, Gallagher JR, Torian U, Myers ML, Conlon MT, Gulati NM, Harris AK. Structural analysis of influenza vaccine virus-like particles reveals a multicomponent organization. Sci Rep 2018;8:10342. [PMID: 29985483 DOI: 10.1038/s41598-018-28700-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
10 Hine BC, Hunt PW, Colditz IG. Production and active transport of immunoglobulins within the ruminant mammary gland. Veterinary Immunology and Immunopathology 2019;211:75-84. [DOI: 10.1016/j.vetimm.2019.04.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
11 Heider S, Dangerfield JA, Metzner C. Biomedical applications of glycosylphosphatidylinositol-anchored proteins. J Lipid Res 2016;57:1778-88. [PMID: 27542385 DOI: 10.1194/jlr.R070201] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
12 Calzas C, Chevalier C. Innovative Mucosal Vaccine Formulations Against Influenza A Virus Infections. Front Immunol 2019;10:1605. [PMID: 31379823 DOI: 10.3389/fimmu.2019.01605] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
13 Mohan T, Berman Z, Luo Y, Wang C, Wang S, Compans RW, Wang BZ. Chimeric virus-like particles containing influenza HA antigen and GPI-CCL28 induce long-lasting mucosal immunity against H3N2 viruses. Sci Rep 2017;7:40226. [PMID: 28067290 DOI: 10.1038/srep40226] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]